Enhanced Cytotoxic Function of Natural Killer and CD3+CD56+ Cells in Cord Blood after Culture

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 1, 2015, Pages 39-49

  Tomchuck, Suzanne L ^a   Leung, Wing H ^a,b   Dallas, Mari H ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Cord blood; Cytotoxicity; Exvivo expansion; Killer cell immunoglobulin like receptors (KIR); Natural killer

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; IL5 PROTEIN, HUMAN; INTERLEUKIN 5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; NCAM1 PROTEIN, HUMAN;

ARTICLE; CELL EXPANSION; COCULTURE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; EX VIVO STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MONONUCLEAR CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; CELL CULTURE; CYTOLOGY; CYTOTOXICITY; DRUG EFFECTS; FETUS BLOOD; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; TUMOR CELL LINE;

ANTIGENS, CD3; ANTIGENS, CD56; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FETAL BLOOD; GENE EXPRESSION; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; INTERLEUKIN-5; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; RECEPTORS, KIR; RECEPTORS, NATURAL CYTOTOXICITY TRIGGERING; RECEPTORS, NK CELL LECTIN-LIKE;

EID: 84927154659     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.10.014     Document Type: Article

References (33)

1. Borrego F., Kabat J., Kim D.K., et al. Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002, 38:637-660.
2. Romagne F., Andre P., Spee P., et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 2009, 114:2667-2677.
3. Merindol N., Charrier E., Duval M., Soudeyns H. Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. JLeukoc Biol 2011, 90:49-60.
4. Danby R., Rocha V. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol 2014, 5:68.
5. Clausen J., Wolf D., Petzer A.L., et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007, 148:520-528.
6. Ruggeri L. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
7. Dalle J.-H., Menezes J., Wagner R., et al. Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res 2005, 57:649-655.
8. López M.C., Palmer B.E., Lawrence D.A. Phenotypic differences between cord blood and adult peripheral blood. Cytometry B Clin Cytom 2009, 76B:37-46.
9. Xing D., Ramsay A.G., Gribben J.G., et al. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. JImmunother 2010, 33:684-696.
10. Wang Y., Xu H., Zheng X., et al. High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol 2007, 4:377-382.
11. Carlens S.S., Gilljam M.M., Chambers B.J.B., et al. Anew method for invitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 2001, 62:1092-1098.
12. Luevano M., Daryouzeh M., Alnabhan R., et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol 2012, 73:248-257.
13. Luevano M., Domogala A., Blundell M., et al. Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells invitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells. PloS One 2014, 9:e87086.
14. Ayello J., van de Ven C., Fortino W., et al. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following exvivo cellular engineering. Biol Blood Marrow Transplant 2006, 12:608-622.
15. Fujisaki H., Kakuda H., Imai C., et al. Replicative potential of human natural killer cells. Br J Haematol 2009, 145:606-613.
16. Fujisaki H., Kakuda H., Shimasaki N., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010.
17. Imai C., Iwamoto S., Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005, 106:376.
18. Shah N., Martin-Antonio B., Yang H., et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PloS One 2013, 8:e76781.
19. Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
20. Eissens D.N., Spanholtz J., van der Meer A., et al. Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PloS One 2012, 7:e30930.
21. Spanholtz J., Tordoir M., Eissens D., et al. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One 2010, 5:e9221.
22. Poli A., Michel T., Theresine M., et al. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009, 126:458-465.
23. Ayello J., van de Ven C., Cairo E., et al. Characterization of natural killer and natural killer-like T cells derived from exvivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol 2009, 37:1216-1229.
24. Rujkijyanont P., Chan W.K., Eldridge P.W., et al. Exvivo activation of CD56(+) immune cells that eradicate neuroblastoma. Cancer Res 2013, 73:2608-2618.
25. Kim S., Poursine-Laurent J., Truscott S.M., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
26. Della Chiesa M., Falco M., Podesta M., et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood 2012, 119:399-410.
27. Bjorklund A.T., Schaffer M., Fauriat C., et al. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 2010, 115:2686-2694.
28. Chan W.K., Rujkijyanont P., Neale G., et al. Multiplex and genome-wide analyses reveal distinctive properties of KIR+ and CD56+ T cells in human blood. JImmunol 2013, 191:1625-1636.
29. Tang Q., Grzywacz B., Wang H., et al. Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional. JImmunol 2008, 181:4507-4515.
30. Musha N., Yoshida Y., Sugahara S., et al. Expansion of CD56+ NK T and gamma delta T cells from cord blood of human neonates. Clin Exp Immunol 1998, 113:220-228.
31. D'Ombrain M.C., Hansen D.S., Simpson K.M., Schofield L. Gammadelta-T cells expressing NK receptors predominate over NK cells and conventional T cells in the innate IFN-gamma response to Plasmodium falciparum malaria. Eur J Immunol 2007, 37:1864-1873.
32. Choi I., Yoon S.R., Park S.Y., et al. Donor-derived natural killer cells infused after human leukocyte antigenehaploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant 2014, 20:696-704.
33. Yoon S.R., Lee Y.S., Yang S.H., et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 2010, 45:1038-1046.